MyFinsight
Home
Blog
About
Net decrease in
cash, cash...
-$35,869K
Change in fair value of
embedded derivatives and...
-$32,035K
Interest expense added to
debt principal
$4,392K
Accrued expenses and
other liabilities
$3,767K
Accounts payable
$3,381K
Amortization of debt issuance
costs and discounts
$2,557K
Stock-based compensation
expense
$1,929K
Prepaid expenses and
other assets
-$1,119K
Operating lease
right-of-use assets
-$149K
Proceeds from the
exercise of stock options...
$574K
Net cash used in
operating activities
-$24,931K
Net cash (used in)
provided by investing...
-$10,036K
Net cash provided by
financing activities
-$898K
Effect of exchange
rates on cash, cash...
-$4K
Canceled cashflow
$49,329K
Canceled cashflow
$574K
Net loss
-$67,023K
Purchases of investments
$10,036K
Payment of equity
issuance costs
$1,472K
Accounts receivable, net
$6,514K
Inventory
$395K
Operating lease
liabilities
-$235K
Net amortization of
premiums and discounts on...
$90K
Depreciation
-$3K
Back
Back
Cash Flow
Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI)
source: myfinsight.com